Lexeo Therapeutics Inc. C... (LXEO)
2.29
-0.26 (-10.20%)
At close: Apr 16, 2025, 3:59 PM
2.28
-0.22%
After-hours: Apr 16, 2025, 04:05 PM EDT
-10.20% (1D)
| Bid | 2.27 |
| Market Cap | 75.86M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -98.33M |
| EPS (ttm) | -3.09 |
| PE Ratio (ttm) | -0.74 |
| Forward PE | -0.85 |
| Analyst | Buy |
| Ask | 2.33 |
| Volume | 519,907 |
| Avg. Volume (20D) | 719,139 |
| Open | 2.55 |
| Previous Close | 2.55 |
| Day's Range | 2.19 - 2.43 |
| 52-Week Range | 1.45 - 19.50 |
| Beta | 1.52 |
About LXEO
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associat...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 3, 2023
Employees 72
Stock Exchange NASDAQ
Ticker Symbol LXEO
Website https://www.lexeotx.com
Analyst Forecast
According to 5 analyst ratings, the average rating for LXEO stock is "Buy." The 12-month stock price forecast is $21, which is an increase of 819.04% from the latest price.
Stock Forecasts3 weeks ago
+50.92%
Lexeo Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
5 months ago
-0.65%
Lexeo Therapeutics shares are trading higher. Leerink Partners maintained an Outperform rating on the stock.
